M1型肿瘤相关巨噬细胞在肝细胞癌组织中浸润的意义

肖锋, 许桐林, 朱琳, 肖静文, 吴天祺, 顾春燕

  1. 1.南通市第三人民医院,南通大学附属南通第三医院病理科,江苏 南通 226006
    2.南通市第三人民医院,南通大学附属南通第三医院外科,江苏 南通 226006
    3.南通大学医学院临床医学专业,江苏 南通 226006
  • 收稿日期:2024-02-29 修回日期:2024-07-03 出版日期:2024-08-30 发布日期:2024-09-10
  • 通信作者: 顾春燕
  • 作者简介:肖锋(ORCID: 0009-0009-2680-609X),硕士,副主任医师,南通市第三人民医院病理科副主任。
  • 基金资助:
    南通市市级科技计划项目(JC22022025);南通市卫健委科研项目(MS2022069 MS2023070)

摘要/Abstract

摘要:

背景与目的:肿瘤相关巨噬细胞(tumor-associated macrophages,TAM)是肿瘤微环境中的主要基质细胞,在肿瘤进展过程中发挥重要作用,本研究旨在探究肝细胞癌(hepatocellular carcinoma,HCC)中M1型TAM浸润的临床意义。方法:收集2012年1月—2020年12月在南通大学附属南通第三医院接受手术的HCC患者石蜡包埋组织样本320例,采用免疫组织化学法检测CD86标记的M1型TAM在HCC组织中分布情况,计算阳性细胞密度,根据细胞密度分组:大于平均密度(29个/mm2)判定为高密度组,小于或等于平均密度为低密度组;统计分析M1型TAM密度与HCC临床病理学特征、肿瘤浸润CD8T淋巴细胞之间的相关性及预后意义;采用免疫组织化学法检测程序性死亡配体-1(programmed death ligand-1,PD-L1)的表达情况,根据CD86、PD-L1细胞密度将病例分4组:CD86高密度组中PD-L1高密度(CD86highPD-L1high)和PD-L1低密度(CD86highPD-L1low)组;CD86低密度组中PD-L1高密度(CD86lowPD-L1high)和PD-L1低密度(CD86lowPD-L1low)组,分析CD86 M1型TAM密度联合PD-L1表达的预后意义。本研究通过南通大学附属南通第三医院伦理委员会批准(伦理编号:EK2022005)。结果:CD86M1型TAM主要分布于肿瘤间质中;其高密度率为44.7%(143/320)。CD86M1型TAM密度与CD8肿瘤浸润细胞毒性T淋巴细胞密度呈正相关(P<0.001)、与乙型肝炎病毒表面抗原(hepatitis B virus surface antigen,HBsAg)阳性呈负相关(P=0.003),与患者性别、年龄、肝硬化、肿瘤大小、组织学分级、微血管侵犯等临床病理学指标均无明显相关性;CD86M1型TAM高密度组患者总生存期(overall survival,OS)、无病生存期(disease-free survival,DFS)优于低密度组,差异均有统计学意义(P均<0.001)。多因素Cox比例风险回归模型分析显示,低密度CD86M1型TAM是评估OS和DFS的独立风险因子(OS:HR=1.468,P=0.022;DFS:HR=2.233,P<0.001)。CD86highPD-L1high组HCC患者OS、DFS差于CD86highPD-L1low组,两者差异有统计学意义(P均<0.05)。CD86lowPD-L1high组OS、DFS差于CD86lowPD-L1low组,两者OS差异有统计学意义(P<0.05),DFS差异无统计学意义。结论:HCC组织中存在高密度CD86M1型TAM提示患者预后良好,并且是独立的预后因子。HCC组织表达PD-L1提示肿瘤侵袭性增强,患者预后差。

关键词: 巨噬细胞, 程序性死亡配体1, 肝细胞癌, 预后

Abstract:

Background and purpose: Tumor-associated macrophages (TAM) as the main stromal cells in the tumor microenvironment play an important role in tumor progression. This study aimed to explore the clinical significance of M1 type TAM infiltration in hepatocellular carcinoma (HCC). Methods: We collected tissue paraffin samples from 320 HCC patients who underwent surgery at the Affiliated Nantong Hospital Three of Nantong University from January 2012 to December 2020. Immunohistochemical methods were used to detect the distribution of CD86 labeled M1 type TAM in HCC tissues, and positive cell density was calculated. Groups were established according to cell density, high-density group had cells with greater than average density (29 cells/mm2), and low-density group had cells with less than or equal to average density. The correlation and prognostic significance of M1 TAM density with clinicopathologic features and tumor infiltrating CD8 T lymphocytes of HCC were analyzed. Using immunohistochemistry to detect the expression of programmed death ligand-1 (PD-L1), the cases were divided into four groups based on the cell density of CD86 and PD-L1. In the CD86 high-density group, PD-L1 high-density (CD86highPD-L1high) and PD-L1 low-density (CD86highPD-L1low) groups were included. In the CD86 low-density group, the PD-L1 high-density (CD86lowPD-L1high) and PD-L1 low-density (CD86lowPD-L1low) groups were included. We analyzed the prognostic significance of CD86 M1 type TAM density combined with PD-L1 expression. This study was approved by the Ethics Committee of Affiliated Nantong Hospital Three of Nantong University (ethics number: EK2022005). Results: CD86 M1 type TAM was mainly distributed in the tumor stroma. Its high-density rate was 44.7% (143/320). The density of CD86 M1 type TAM was positively correlated with tumor infiltrating CD8 T lymphocyte density (P<0.001) and negatively correlated with hepatitis B virus surface antigen (HBsAg) positivity (P=0.003), and had no significant correlation with clinical and pathological features such as patient age, gender, cirrhosis, tumor size, histological grading and microvascular invasion. The CD86 M1 type TAM high-density group had better overall survival (OS) and disease-free survival (DFS) than the low-density group, and the differences were statistically significant (all P<0.001). Multivariate Cox proportional hazards regression model analysis showed that low-density CD86 M1 type TAM was an independent risk factor for evaluating OS and DFS (OS: HR=1.468, P=0.022; DFS: HR=2.233, P<0.001). The CD86highPD-L1high group had poor OS and DFS than the CD86highPD-L1low group, and the differences were statistically significant (both P<0.05). The CD86lowPD-L1high group had poor OS and DFS than the CD86lowPD-L1low group. The difference in OS between the two groups was statistically significant (P<0.05), while the difference in DFS was not statistically significant. Conclusion: The presence of high-density CD86 M1 type TAM in HCC tissue suggests a good prognosis and is an independent prognostic factor. Expression of PD-L1 in HCC tissue suggests increased invasiveness and poorer prognosis.

Key words: Macrophage, Programmed death ligand 1, Hepatocellular carcinoma, Prognosis

中图分类号: 

相关文章

[1] 唐楠, 黄慧霞, 刘晓健. 利用单细胞测序和转录组测序建立结直肠癌免疫细胞的9基因预后模型[J]. 中国癌症杂志, 2024, 34(6): 548-560.
[2] 张若昕, 叶紫岚, 翁俊勇, 李心翔. 高龄与Ⅱ期结直肠癌患者预后不良的相关性研究[J]. 中国癌症杂志, 2024, 34(5): 485-492.
[3] 金奕滋, 林明曦, 张剑. 乳腺癌原发灶与肝转移灶受体表达差异研究[J]. 中国癌症杂志, 2023, 33(9): 834-843.
[4] 吴晗, 杨章孺, 冯雯, 曾琬琴, 郭金栋, 李洪选, 王常禄, 王家明, 吕长兴, 张琴, 余雯, 蔡旭伟, 傅小龙. 多原发性早期肺癌立体定向放射治疗后疗效及患者预后分析[J]. 中国癌症杂志, 2023, 33(9): 844-856.
[5] 陈金娟, 王星然, 李文质, 程煜, 孙艺华, 陶祥, 马凤华, 孙莉, 赵洪波, 鹿欣. 保守手术治疗的10例Ⅰ期胎盘部位滋养细胞肿瘤病例报告及文献复习[J]. 中国癌症杂志, 2023, 33(9): 857-865.
[6] 孙洋, 王炼, 赵萌, 张小凤, 耿志军, 王月月, 宋雪, 左芦根, 李静, 胡建国. 胃癌中FKBP1A高表达的预后价值及其靶向PI3K/AKT对糖代谢的调控作用[J]. 中国癌症杂志, 2023, 33(8): 726-739.
[7] 姜琳, 刘绮颖, 贾利晴, 张静, 常恒, 薛田, 任敏, 柏乾明, 朱晓丽, 周晓燕. 胶质瘤中MGMT甲基化状态及其临床意义的回顾性研究[J]. 中国癌症杂志, 2023, 33(8): 740-750.
[8] 王若曦, 吉芃, 龚悦, 陈盛. HER2低表达乳腺癌新辅助化疗效果及其预后特征:一项单中心回顾性研究[J]. 中国癌症杂志, 2023, 33(7): 686-692.
[9] 左学良, 陈志强, 董润雨, 王智雄, 蔡娟. 联合检测LDHA和PD-L1在晚期胃癌PD-1抑制剂疗效预测及预后评估中的价值[J]. 中国癌症杂志, 2023, 33(5): 460-468.
[10] 赵海潮, 高强. 2022年度肝癌研究及诊疗新进展[J]. 中国癌症杂志, 2023, 33(4): 315-326.
[11] 陈玉光, 孙晓, 毕钊, 邱鹏飞, 段宝伟, 樊庆达, 王永胜. 乳腺癌内乳前哨淋巴结活检评估预后及指导个体化内乳照射:一项长期随访研究[J]. 中国癌症杂志, 2023, 33(2): 142-151.
[12] 高鹤丽, 徐近, 陈洁, 虞先濬. 胰腺神经内分泌瘤的精准诊疗进展[J]. 中国癌症杂志, 2023, 33(11): 993-1001.
[13] 胡可舒, 刘文凤, 张锋, 权冰, 殷欣. 长链非编码RNA LINC00601调控肝细胞癌奥沙利铂耐药的分子机制研究[J]. 中国癌症杂志, 2023, 33(1): 25-35.
[14] 陈瑛瑶, 储香玲, 俞昕, 苏春霞. 免疫检查点抑制剂疗效相关预测模型的研究进展[J]. 中国癌症杂志, 2023, 33(1): 61-70.
[15] 高鹤丽, 徐近, 虞先濬. 2021年胰腺神经内分泌肿瘤诊治的新进展[J]. 中国癌症杂志, 2022, 32(9): 772-778.